Sponsored Links
| Interim Data From Phase 2 Trial Of AC220 Monotherapy In Patients With Relapsed Or Refractory Acute Myeloid Leukemia With FLT3-ITD Activating Mutations |
 |
 |
 |
| Medical News - Hematology | |||
|
Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor... Read more: Blood / Hematology News From Medical News Today
|